ID: h-7693c291
Hypothesis
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism.
EvidencePending (0%)📖 20 cit🗣 3 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["TDP-43 / TARDBP"] --> B["RNA Processing Functions"]
B --> C["Splicing Regulation"]
B --> D["RNA Transport"]
B --> E["RNA Stability"]
F["Pathological Conditions"] --> G["Cytoplasmic Mislocalization"]
G --> H["Hyperphosphorylation"]
H --> I["TDP-43 Aggregation"]
I --> J["Cross-Seeding with Other Proteins"]
J --> K["ALS/FTD Pathology"]
L["RNA-Binding Competition Therapy"] --> M["Designed RNA Decoys"]
M --> N["Compete for TDP-43 RNA-Binding Domain"]
N --> O["Sequester TDP-43 in Soluble Form"]
O --> P["Prevent Cytoplasmic Aggregation"]
O --> Q["Block Cross-Seeding"]
O --> R["Preserve Some RNA Processing"]
P --> S["Reduced TDP-43 Inclusions"]
Q --> T["Prevented Prion-like Spread"]
R --> U["Maintained Cellular Function"]
S --> V["Neuroprotection in ALS/FTD"]
T --> V
U --> V
style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
style F fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
style L fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Contradicts
TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic
Contradicts
TDP-43 pathology often involves loss rather than gain of RNA binding function
📖 Linked Papers (23)Export BibTeX ↗
The Genetics of TDP-43 Type C Neurodegeneration: A Whole-Genome Sequencing Study and Literature Review.
Neurology. Genetics (2026) · PubMed:41883703 ↗
1 figure

Figure 1
Imaging and Pathological Data for the TDP-C Cases With Rare Genetic Variants of Interest (A) Neuroimaging for the probable TDP-C case of svPPA with FIG4 varia...
ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies.
Current opinion in neurobiology (2026) · PubMed:41570741 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Magnetic control of tokamak plasmas through deep reinforcement learning.
Nature (2022) · PubMed:35173339 ↗
9 figures

Fig. 1
Representation of the components of our controller design architecture. a , Depiction of the learning loop. The controller sends voltage commands on the basis o...

Fig. 2
Fundamental capability demonstration. Demonstration of plasma current, vertical stability, position and shape control. Top, target shape points with 2 cm radius...
TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.
Nature neuroscience (2022) · PubMed:34916658 ↗
17 figures

Extended Data Fig. 1
Characterizations of GFP-hTDP-43 expression in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection of AAV9.C...

Extended Data Fig. 2
Characterizations of motor deficits and neuronal loss in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection...
TDP-43 Pathology in Alzheimer's Disease.
Mol Neurodegener (2021) · PubMed:34930382 ↗
4 figures

Fig. 1
Protein structure of transactive response DNA binding protein of 43 kDa (TDP-43). TDP-43 is a 414 amino acid protein with a nuclear localization sequence (NLS) ...

Fig. 2
Representative images of TDP-43 pathology subtypes in FTLD-TDP brains. (A) Immunohistochemistry with an anti-phosphorylated-TDP-43 antibody (pSer409/pSer410) sh...
SMS2 deficiency impairs PKCδ-regulated B cell tolerance in the germinal center.
Cell reports (2021) · PubMed:34469734 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Cardiomyocyte-derived calcitonin regulates atrial fibrosis and AF.
Nature reviews. Cardiology (2021) · PubMed:33199879 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS.
Cell (2020) · PubMed:33031745 ↗
12 figures

Figure 1
No caption available

Figure S1
Elevated NF-κB and Type I IFN Signaling Because of TDP-43 In Vitro , Related to Figure 1 (A) Doxycycline (Dox inducible wild-type (WT) or ALS mutant (Q331K) T...
Protein transmission in neurodegenerative disease.
Nat Rev Neurol (2020) · PubMed:32203399 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Characterizing the RNA targets and position-dependent splicing regulation by TDP-43.
Nature neuroscience (2011) · PubMed:21358640 ↗
4 figures

Figure 1
Comparison of TDP-43 RNA binding in healthy and FTLD-TDP brain (a) To validate specificity of TDP-43 antibody for iCLIP, the 32 P-labelled RNA bound to TDP-43...

Figure 2
TDP-43 binding motif analysis (a) z-scores of penamer occurrence within the 61 nt sequence surrounding all crosslink sites (−30 nt to +30 nt) are shown for hea...
Amyotrophic lateral sclerosis.
Orphanet journal of rare diseases (2009) · PubMed:19192301 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
📙 Related Wiki Pages (15)
EEDgeneANXA11 — Annexin A11geneAlibaba Tongyi Qianwen-Bio (Chinese Biomai_toolALS8 - Amyotrophic Lateral Sclerosis 8geneTARDBP Mutations in Amyotrophic Lateral diseaseANO8 (Anoctamin 8)geneALS10 - Amyotrophic Lateral Sclerosis 10geneFamilial vs Sporadic Neurodegeneration Cdiseasemitochondrial-dysfunction-neurodegeneratdiseaseGene Page: ALS4 (SENATAXIN)geneFTD Dataset RankingsdatasetUPenn Observational Research Repository clinicalNeurodegenerationdiseaseAmyotrophic Lateral SclerosisredirectALS9 - Amyotrophic Lateral Sclerosis 9gene
🏥 Translation
🧬 3D Protein Structure — TARDBP
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TARDBP from GTEx v10.
💉 Clinical Trials (3)Relevance: 24%
0
Active
Active
0
Completed
Completed
1,610
Total Enrolled
Total Enrolled
ENROLLING_BY_INVITATION·NCT06875739 · Fondazione Don Carlo Gnocchi Onlus
310 enrolled · 2025-02-14 · → 2026-10-01
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's
Neurodegenerative Disorders Parkinson Disease Alzheimer Disease
RECRUITING·NCT06339190 · Monash University
1,000 enrolled · 2021-08-01 · → 2025-12
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level
Neurodegenerative Diseases Dementia
Venepuncture
RECRUITING·NCT03865420 · Columbia University
300 enrolled · 2018-09-11 · → 2027-01
This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it pr
ALS
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TARDBP.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.3%
Volatility
High
0.0726
Events (7d)
2
Price History
▼28.6%💾 Resource Usage
LLM Tokens
36,356
$0.2181
Total Cost
$0.2181
🔮 Predictions
🔎 Predictions vs Observations4 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX) | be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SE | — no observation — | pending | 0.40 |
| If hypothesis is true, intervention be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs | be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) m | — no observation — | pending | 0.40 |
| If hypothesis is true, intervention be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities | be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities | — no observation — | pending | 0.40 |
| If hypothesis is true, intervention competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets | competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets | — no observation — | pending | 0.40 |
🔮 Falsifiable Predictions (4)
pendingconf 40%
If hypothesis is true, intervention competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets
Predicted outcome: competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets
Falsification: Intervention fails to competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets
pendingconf 40%
If hypothesis is true, intervention be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)
Predicted outcome: be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enri
Falsification: Intervention fails to be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)
pendingconf 40%
If hypothesis is true, intervention be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs
Predicted outcome: be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclei
Falsification: Intervention fails to be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs
pendingconf 40%
If hypothesis is true, intervention be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities
Predicted outcome: be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities
Falsification: Intervention fails to be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.